TriSalus Life Sciences Inc.
Organization details
- Legal name
- TriSalus Life Sciences Inc.
- Former names
- MedTech Acquisition Corp
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Westminster
- Headquarters state / province
- Colorado
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TLSI
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001826667
- EIN
- 85-3009869
Board of directors
-
Anil K. Singhal · DirectorSince 2023
-
Arjun Jj Desai · DirectorSince 2023
-
David J. Matlin · DirectorSince 2023
-
Eschenbach Andrew C. Von · DirectorSince 2023
-
Gary B. Gordon · DirectorSince 2025
-
George Kelly Martin · DirectorSince 2023
-
Kerry R. Hicks · DirectorSince 2023
-
Liselotte Hyveled · DirectorSince 2024
-
Mary T. Szela · Director · CEO and PresidentSince 2023
-
Mats Wahlstrom · DirectorSince 2023
-
Michael P. Stansky · DirectorSince 2026
-
Sean Murphy · Director · Chief Manuf, Strategy&Bus Dev.Since 2023
-
William Valle · DirectorSince 2025
Chief executives
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
53.9% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Director election results
Annual meeting of May 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
92.2%
-
92.3%
Board connections
6 of this board's directors also sit on 9 other boards. 8 are in the same sector.
-
Clene Inc. Same sectorvia Arjun Jj Desai and David J. Matlin
-
Absci Corporation Same sectorvia Mary T. Szela
- via Mary T. Szela
-
Bausch + Lomb Corporation Same sectorvia Eschenbach Andrew C. Von
-
Celularity Inc. Same sectorvia Eschenbach Andrew C. Von
-
Coherus Oncology Inc. Same sectorvia Mats Wahlstrom
-
Kura Oncology Inc. Same sectorvia Mary T. Szela
-
Longeveron Inc. Same sectorvia Arjun Jj Desai
-
Werewolf Therapeutics Inc. Same sectorvia Anil K. Singhal
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $3,606,918
- 12 purchases by 6 insiders
- Sold, last 12 months
- $139,922
- 18 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 5, 2026 | Cox Bryan F. Officer (Chief of Research) | Open-market sale | −296 | $4.39 | $1,299 |
| Oct 5, 2026 | Marshak Richard Officer (Chief Commercial Officer) | Open-market sale | −325 | $4.39 | $1,427 |
| Oct 5, 2026 | Stevens Jennifer Officer (Chief Regulatory Officer) | Open-market sale | −316 | $4.39 | $1,387 |
| Oct 5, 2026 | Mary T. Szela Director, Officer (CEO and President) | Shares withheld for tax | −2,693 | $4.38 | $11,795 |
| Jul 1, 2026 | Patience David Officer (Chief Financial Officer) | Shares withheld for tax | −14,650 | $4.46 | $65,339 |
| Jun 30, 2026 | Marshak Richard Officer (Chief Commercial Officer) | Grant or award | +561 | $3.87 | $2,171 |
| Jun 30, 2026 | Mary T. Szela Director, Officer (CEO and President) | Grant or award | +3,990 | $3.87 | $15,441 |
| Jun 29, 2026 | Marshall Richard Henry Officer (Chief Medical Officer) | Grant or award | +60,000 | — | — |
| May 15, 2026 | Marshak Richard Officer (Chief Commercial Officer) | Open-market sale | −543 | $2.67 | $1,450 |
| May 15, 2026 | Mats Wahlstrom Director | Open-market purchase | +60,000 | $2.53 | $151,800 |
| May 15, 2026 | Michael P. Stansky Director | Open-market purchase | +410,000 | $2.50 | $1,025,000 |
| May 15, 2026 | Mary T. Szela Director, Officer (CEO and President) | Open-market purchase | +39,682 | $2.59 | $102,776 |
| May 15, 2026 | Patience David Officer (Chief Financial Officer) | Open-market purchase | +7,100 | $2.43 | $17,253 |
| May 15, 2026 | Gary B. Gordon Director | Open-market purchase | +10,000 | $2.46 | $24,600 |
| May 15, 2026 | Michael P. Stansky Director | Open-market purchase | +200,000 | $2.50 | $500,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about TriSalus Life Sciences Inc.
Who is the CEO of TriSalus Life Sciences Inc.?
Mary T. Szela has been TriSalus Life Sciences Inc.'s CEO and President since August 2023.
How many directors are on TriSalus Life Sciences Inc.'s board?
TriSalus Life Sciences Inc.'s board has 13 directors: Anil K. Singhal, Arjun Jj Desai, David J. Matlin, Eschenbach Andrew C. Von, Gary B. Gordon, George Kelly Martin, Kerry R. Hicks, Liselotte Hyveled, Mary T. Szela, Mats Wahlstrom and 3 others.
Are TriSalus Life Sciences Inc. insiders buying or selling shares?
Over the last 12 months, TriSalus Life Sciences Inc. insiders bought $3.6 million of shares in 12 purchases and sold $139,922 of shares in 18 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="trisalus-life-sciences-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.